Investigating the expression of lncRNA gene PVT1 and its role in colorectal cancer.
Investigating the expression of lncRNA gene PVT1 and its role in colorectal cancer.
Yousef Paridar,1Mohammad Hossein Shayanpour,2Mohammad Moeen Dabirian,3Farhad Ahmadi,4Maysam Mard-Soltani,5,*Neda Shakerian,6
1. Gastroenterology Clinic, Dezful University of Medical Sciences, Dezful, Iran 2. Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran. 3. Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran. 4. Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran. 5. Department of Clinical Biochemistry, Faculty of Medical Sciences, Dezful University of Medical Sciences, Dezful, Iran 6. Department of Clinical Biochemistry, Faculty of Medical Sciences, Dezful University of Medical Sciences, Dezful, Iran
Introduction: Colorectal cancer (CRC) remains a major global health challenge, ranking as the fourth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis for advanced CRC remains poor. This study aimed to investigate the expression and clinical significance of long non-coding RNA PVT1 in CRC.
Methods: Total RNA was extracted from CRC tissues and adjacent normal tissues using a standard extraction protocol. Complementary DNA (cDNA) was synthesized from the extracted RNA using the geneAll reverse transcription kit (Invitrogen). The qRT-PCR reaction was performed in 0.2 ml tubes using the SYBR Green Master Mix (Denmark, amplitude) on a LightCycler® 96 system (Roche Life Science, Germany). β-actin was used as an endogenous control, and the 2-ΔΔCt method was employed to calculate the relative expression levels of tumor PVT1 and Peripheral PVT1 variants.
Results: The qRT-PCR analysis revealed a significant upregulation of the tumor PVT1 variant in CRC tissues compared to adjacent normal tissues. The tumor PVT1 variant exhibited higher expression levels than the Peripheral PVT1 variant across all CRC samples, suggesting a potential oncogenic role for tumor PVT1 in colorectal carcinogenesis. Statistical analysis demonstrated that elevated tumor PVT1 expression was significantly associated with advanced tumor stage, lymph node metastasis, and poor overall survival. These findings indicate that tumor PVT1 may be involved in the activation of specific signaling pathways that drive tumor progression and metastasis
Conclusion: Discussion
The results of this study highlight the potential role of the tumor PVT1 variant as a key player in CRC progression. The marked upregulation of tumor PVT1 in CRC tissues suggests that this lncRNA may contribute to the aggressive nature of the disease by promoting uncontrolled cell proliferation, enhancing EMT, and supporting metastatic spread (7). The association between elevated tumor PVT1 expression and advanced tumor stage further supports its potential as a prognostic biomarker for CRC.
The findings of this study are consistent with previous reports that have implicated PVT1 in various cancers, including CRC (8). However, the precise molecular mechanisms through which tumor PVT1 exerts its effects in CRC remain to be fully elucidated. It is possible that tumor PVT1 interacts with key oncogenic pathways, such as the Wnt/β-catenin, PI3K/AKT, or MAPK/ERK pathways, to promote tumor growth and survival. Further research is needed to identify these interactions and explore the potential of tumor PVT1 as a therapeutic target (9).
In conclusion, this study provides evidence that the tumor PVT1 variant is significantly upregulated in CRC tissues and is associated with poor clinical outcomes. The findings suggest that tumor PVT1 could serve as a valuable prognostic biomarker and a potential target for therapeutic intervention in CRC. Future studies should focus on elucidating the molecular mechanisms underlying tumor PVT1 role in CRC and investigating its potential as a target for novel therapeutic strategies.